Illinois is currently home to 2679 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Chicago, Peoria, Springfield and Urbana. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Phase I Study of RiMO-301 With Radiation in Advanced Tumors
Recruiting
This is a prospective, open-label, single arm, non-randomized study of RiMO-301 with radiation in patients with advanced tumors. A single escalation dose of RiMO-301 is intratumorally injected in a 3 + 3 study design to identify the recommended dose and dosing volumes. Condition or Disease: Patient with advanced tumor which is clinically accessible for intratumoral injection Intervention/Treatment: Drug - RiMO-301 Radiation - Radiotherapy Phase: Phase 1
Gender:
All
Ages:
18 years and above
Trial Updated:
02/14/2024
Locations: University of Illinois at Chicago, Chicago, Illinois
Conditions: Advanced Tumors
Constraint Induced Movement Therapy for Walking in Individuals Post Stroke
Recruiting
To compare the effect of constraint induced movement therapy (CIMT) vs. treadmill training only on walking function in individuals post-stroke, a 6 week, single-blind, randomized training study will be conducted with three assessments of gait to determine the training effect. Subjects will be randomized to either the CIMT or treadmill training only groups at the initial test. Following the initial test, individuals from the 2 groups will undergo intensive locomotor training. Training will be per... Read More
Gender:
All
Ages:
Between 21 years and 75 years
Trial Updated:
02/14/2024
Locations: Abilitylab, Chicago, Illinois
Conditions: Stroke
Improve Dynamic Lateral Balance of Humans With SCI
Recruiting
This study is to test whether pelvis perturbation training paired with transcutaneous spinal direct current stimulation (tsDCS) will be effective in improving dynamic balance and locomotor function in humans with SCI. One group will receive pelvis perturbation training paired with tsDCS, one group will receive pelvis perturbation training paired with sham, and one group will receive treadmill training only.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
02/14/2024
Locations: Abilitylab, Chicago, Illinois
Conditions: Spinal Cord Injury
Mechanical Coring to Achieve Directional Skin Tightening
Recruiting
The objective of this clinical study is to evaluate the safety and efficacy of mechanical coring for directional skin tightening. This study is a prospective, up to 3 center, multiple skin treatment area study of the safety and efficacy of mechanical coring with directional closure to achieve directional skin tightening.
Gender:
All
Ages:
Between 30 years and 70 years
Trial Updated:
02/13/2024
Locations: DeNova Research, Chicago, Illinois
Conditions: Skin Tightening, Healthy Volunteers
The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
Recruiting
This is an open-label, Phase 1/2 study designed to characterize the safety, tolerability, Pharmacokinetics(PK), and preliminary antitumor activity of AVM0703 administered as a single intravenous (IV) infusion to patients with lymphoid malignancies.
Gender:
All
Ages:
Between 12 years and 95 years
Trial Updated:
02/13/2024
Locations: University of Illinois at Chicago Cancer Center, Chicago, Illinois
Conditions: Lymphoid Malignancies
Patient-Centered Dementia Care Practice Coaching Intervention
Recruiting
The goal of this clinical trial is to compare staff outcomes in long-term care communities who participate in the intervention versus those who do not. The main questions it aims to answer are: 1. Is employee satisfaction impacted by the intervention and 2. Is dementia care confidence impacted by the intervention. Participants will include monthly coaching visits for the intervention group and completion of surveys pre, immediately post and three-months post. Researchers will compare the interve... Read More
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
02/12/2024
Locations: Alzheimer's Association, Chicago, Illinois
Conditions: Dementia, Alzheimer Disease
Neoadjuvant Pembrolizumab and IO102-103 for Squamous Cell Carcinoma of the Head and Neck (SCCHN).
Recruiting
This research is being done to see if it is safe to give investigational combination of study drugs (Pembrolizumab and IO102-103) before surgery to people with surgically resectable (removable) newly diagnosed or recurrent metastatic SCCHN. This will be done by watching participants closely for possible side effects from Pembrolizumab and IO102-103. In addition, participants will be monitored for any delays to their surgery due to the study drugs.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/12/2024
Locations: Northwestern Memorial Hospital, Chicago, Illinois
Conditions: Head and Neck Squamous Cell Carcinoma
A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma.
Recruiting
This study will assess the efficacy and safety of dexpramipexole as an adjunctive oral therapy in participants with inadequately controlled asthma with an eosinophilic phenotype and a history of asthma exacerbations.
Gender:
All
Ages:
Between 12 years and 99 years
Trial Updated:
02/09/2024
Locations: Research Site 20001-090, Berwyn, Illinois
Conditions: Eosinophilic Asthma, Asthma; Eosinophilic, Asthma
Strength and Muscle Related Outcomes for Nutrition and Lung Function in CF
Recruiting
The goal of the study is to examine multiple markers of anthropometrics, body composition, sarcopenia and frailty and compare them to dual energy X-ray absorptiometry (DXA) output, which is considered the current clinical gold-standard tool to measure body composition. The result of this study will provide detailed data regarding the nutrition and body composition within this Cystic Fibrosis population and also provide a baseline evaluation for use of these biomarkers in the future studies inclu... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/09/2024
Locations: Northwestern University, Chicago, Illinois
Conditions: Cystic Fibrosis
AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Recruiting
AB-101 is an off-the shelf, allogeneic cell product made of "natural killer" cells, also called NK cells. White blood cells are part of the immune system and NK cells are a type of white blood cell that are known to kill cancer cells. This clinical trial will enroll patients with relapsed/refractory non-Hodgkin lymphoma of B-cell origin and is conducted in two phases. The primary objectives of Phase 1 are as follows: 1) to evaluate the safety of AB-101 given alone or in combination with rituxim... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/09/2024
Locations: Rush University Medical Center, Chicago, Illinois
Conditions: Non Hodgkin Lymphoma
Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer
Recruiting
The goal of this clinical trial is to learn about the side effects and effectiveness of this novel four-drug combination of chemotherapy (decitabine, selinexor, carboplatin and paclitaxel) on patients with relapsed ovarian, fallopian or primary peritoneal carcinoma. Recently the investigators have found that the combination of decitabine and selinexor, two Food and Drug Administration (FDA) approved chemotherapy agents, may prevent or reverse the development of drug resistance and further the r... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/07/2024
Locations: Loyola University Medical Center, Maywood, Illinois
Conditions: Ovarian Cancer
Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study
Recruiting
This phase III trial compares the effect of the combination of ramucirumab and pembrolizumab versus standard of care chemotherapy for the treatment of non-small cell lung cancer that is stage IV or that has come back after a period of improvement (recurrent). Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may in... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/06/2024
Locations: Rush - Copley Medical Center, Aurora, Illinois
Conditions: Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8